https://www.selleckchem.com/pr....oducts/Tanshinone-I.
Following one month treatment with 9Q, the amyloid burden and the cognitive deficits in 3xTg-AD mice were significantly ameliorated. It was observed that 9Q treatment mitigated synapse dysfunction, decreased amyloidogenic APP processing, and reduced the tau pathology in 3xTg-AD mice. Taken together, our results suggested that dual inhibition of cholinesterases and Aβ aggregation could be a promising approach in AD treatment.We report on an approach to bring together single crystal metal catalyst preparation and graphene growth in a
Like
Comment
Share
